Coronary anatomy: Difference between revisions

Line 244: Line 244:
   
   
In 2012, the PROTECT II trial randomized 452 patients with 3-vessel of left main coronary artery disease and severely depressed left ventricular function to an Impella (2.5L) or an IABP. The Impella provided superior hemodynamic support, but with no difference in the 30 days endpoint of major adverse events<cite>Cardiol</cite>.
In 2012, the PROTECT II trial randomized 452 patients with 3-vessel of left main coronary artery disease and severely depressed left ventricular function to an Impella (2.5L) or an IABP. The Impella provided superior hemodynamic support, but with no difference in the 30 days endpoint of major adverse events<cite>Cardiol</cite>.
In 2008, a multicenter registry showed the Impella 2.5 to be safe and potentially useful in hemodynamic support in high-risk PCI (multivessel, left main, last remaining vessel, low LV function) with rates of myocardial infarction, stroke, bleeding and vascular complications at 30 days of 6.2%<cite>Oneill</cite>.
In 2008, a multicenter registry showed the Impella 2.5 to be safe and potentially useful in hemodynamic support in high-risk PCI (multivessel, left main, last remaining vessel, low LV function) with rates of myocardial infarction, stroke, bleeding and vascular complications at 30 days of 6.2%<cite>Oneill</cite>. [[File:Impella.jpg|thumb|400px|Example of a 2.5L Impella system<cite>McCulloch</cite>]]
[[File:Impella.jpg|400px|Example of a 2.5L Impella system<cite>McCulloch</cite>]]


= References =
= References =